Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q969T4

UPID:
UB2E3_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme E3; UbcH9; Ubiquitin carrier protein E3; Ubiquitin-conjugating enzyme E2-23 kDa; Ubiquitin-protein ligase E3

ALTERNATIVE UPACC:
Q969T4; B2RAD6; D3DPG3; Q5U0R7; Q7Z4W4

BACKGROUND:
Ubiquitin-conjugating enzyme E2 E3, known alternatively as UbcH9 or Ubiquitin carrier protein E3, is integral to the ubiquitin-proteasome system. This enzyme accepts ubiquitin from the E1 complex and attaches it to substrates, facilitating 'Lys-11', 'Lys-48', and 'Lys-63' linked polyubiquitination. Its function is crucial in the regulation of various cellular processes, including transepithelial sodium transport and potentially cell growth arrest.

THERAPEUTIC SIGNIFICANCE:
The exploration of Ubiquitin-conjugating enzyme E2 E3's functions offers a promising avenue for therapeutic intervention. Given its central role in protein ubiquitination, targeting this enzyme could lead to innovative treatments for diseases where protein homeostasis is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.